R
RVMD
RVMDUnverified9 segments tracked|2 years of data|Annual (10-K)
Total Revenue
$540M86.4%
FY2024
Operating Segments
9Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%Daraxonrasib (RMC-6236)
Segment Shift
Daraxonrasib (RMC-6236) has grown from 0.0% to 31.3% of total revenue since FY2023, with 0.0% operating margins.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| Daraxonrasib (RMC-6236) | $169M | $0 | 0.0% | 31.3% | +0.0% |
| Salaries and other employee-related expenses | $113M | $0 | 0.0% | 21.0% | +0.0% |
| Preclinical programs | $73M | $0 | 0.0% | 13.5% | +0.0% |
| Zoldonrasib (RMC-9805) | $64M | $0 | 0.0% | 11.9% | +0.0% |
| Other research and development costs | $59M | $0 | 0.0% | 10.8% | +0.0% |
| Elironrasib (RMC-6291) | $55M | $0 | 0.0% | 10.2% | +0.0% |
| RAS companion inhibitors | $7M | $0 | 0.0% | 1.3% | +0.0% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free